Affymax (AFFY) Continues Higher on OMONTYS Approval
Tweet
Share
E-mailGet Alerts AFFY Hot Sheet
Join SI Premium – FREE
Affymax, Inc. (Nasdaq: AFFY) is showing continued strength Tuesday, following OMONTYS news issued earlier
According to a release Tuesday morning, Affymax and Takeda Pharmaceutical Company Limited, announced that OMONTYS (peginesatide) Injection is now available only for use in treating anemia due to chronic kidney disease (CKD) in adult patients on dialysis.
Shares are 10.8 percent higher on the session.
According to a release Tuesday morning, Affymax and Takeda Pharmaceutical Company Limited, announced that OMONTYS (peginesatide) Injection is now available only for use in treating anemia due to chronic kidney disease (CKD) in adult patients on dialysis.
Shares are 10.8 percent higher on the session.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Planet Green halted again, now up 793%
- China Conducts Cybersecurity Review Into Palo Alto’s Products
Create E-mail Alert Related Categories
Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
